title: Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia.
abstract: Resveratrol has been purported to modify risk factors for obesity and cardiovascular disease. We sought to examine the effects of resveratrol in a porcine model of metabolic syndrome and chronic myocardial ischemia. Yorkshire swine were fed either a normal diet (control), a high cholesterol diet (HCD), or a high cholesterol diet with supplemental resveratrol (HCD-R; 100mg/kg/day) for 11 weeks. After 4 weeks of diet modification a baseline cardiovascular MRI was performed and an ameroid constrictor was placed on the left circumflex coronary artery of each animal to induce chronic myocardial ischemia. At 7 weeks, a second cardiovascular MRI was performed and swine were sacrificed and myocardial tissue harvested. Resveratrol supplementation resulted in lower body mass indices, serum cholesterol, and C-reactive protein levels, improved glucose tolerance and endothelial function, and favorably augmented signaling pathways associated with myocardial metabolism. Interestingly, serum tumor necrosis factor-α levels were not influenced by resveratrol treatment. Immunoblotting for markers of metabolism demonstrated that insulin receptor substrate-1, glucose transporters 1 and 4, and phospho-AMPK were increased in the HCD-R group. Peroxisome proliferator-activated receptor γ and retinol binding protein 4 were downregulated in the HCD-R group as compared to the HCD group. Myocardial perfusion and function at rest as assessed with magnetic resonance imaging were not different between groups. By favorably influencing risk factors, resveratrol may decrease the burden of chronic metabolic disease and improve cardiovascular health.
authors.affiliation: Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert School of Medicine, Brown University, Providence, RI, USA.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Robich
authors.forename: Robert M
authors.initials: RM
authors.lastname: Osipov
authors.forename: Louis M
authors.initials: LM
authors.lastname: Chu
authors.forename: Yuchi
authors.initials: Y
authors.lastname: Han
authors.forename: Jun
authors.initials: J
authors.lastname: Feng
authors.forename: Reza
authors.initials: R
authors.lastname: Nezafat
authors.forename: Richard T
authors.initials: RT
authors.lastname: Clements
authors.forename: Warren J
authors.initials: WJ
authors.lastname: Manning
authors.forename: Frank W
authors.initials: FW
authors.lastname: Sellke
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003324:Coronary Artery Disease / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D004032:Diet / Q000009:adverse effects; D019587:Dietary Supplements; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005786:Gene Expression Regulation / Q000187:drug effects; D005951:Glucose Tolerance Test; D051275:Glucose Transporter Type 4 / Q000378:metabolism; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D007249:Inflammation / Q000378:metabolism; D007328:Insulin / Q000097:blood; D008279:Magnetic Resonance Imaging; D024821:Metabolic Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D055806:Microvessels / Q000187:drug effects / Q000503:physiopathology; D032342:Muscle Cells / Q000187:drug effects / Q000378:metabolism; D017202:Myocardial Ischemia / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010084:Oxidation-Reduction / Q000187:drug effects; D021381:Protein Transport / Q000187:drug effects; D000077185:Resveratrol; D012307:Risk Factors; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D013552:Swine
chemical_list: D015415:Biomarkers; D005230:Fatty Acids, Nonesterified; D051275:Glucose Transporter Type 4; D007328:Insulin; D013267:Stilbenes; D002784:Cholesterol; D000077185:Resveratrol